Abstract: The present invention is an aqueous solution which contains two types of methyl celluloses, polyethylene glycol, polyvinylpyrrolidone, and citric acid or a pharmaceutically acceptable salt thereof. The composition of the present invention maintains a low viscosity around room temperature, but the composition is suddenly increased in the viscosity due to heat around the body temperature and has thixotropy even after gelation.

Abstract: A composition for optic nerve cell protection, for preventing or treating glaucoma, for suppressing retinal ganglion cell death, or for delaying a progression of visual acuity loss of human contains at least one selected from the group consisting of products obtained by steaming and drying wheat, defatted wheat germ, defatted rice germ, defatted soybean, fermented grape, hesperidin, lactic acid bacterium Lactobacillus salivarius, wild grape, Tamarind, Haskap, pomegranate seeds, licorice powder, and cinnamon powder.

Abstract: The present invention is an aqueous solution which contains two types of methyl celluloses, polyethylene glycol, polyvinylpyrrolidone, and citric acid or a pharmaceutically acceptable salt thereof. The composition of the present invention maintains a low viscosity around room temperature, but the composition is suddenly increased in the viscosity due to heat around the body temperature and has thixotropy even after gelation.

Abstract: The present invention provides compositions incorporating lactic acid bacteria or bifidobacteria with components that act to enhance the function of lactic acid bacteria or bifidobacteria. The present invention relates to a composition containing at least one component selected from the group consisting of lutein, fish oil, lactoferrin, vitamins, ?-aminobutyric acid, and zinc, and a strain of lactic acid bacteria or bifidobacteria.

Abstract: The invention provides a latanoprost-containing aqueous pharmaceutical composition filled in a filter-equipped container, with the adsorption of latanoprost by the filter being prevented. In the latanoprost-containing aqueous pharmaceutical composition filled in the filter-equipped container, a nonionic surfactant is contained in the composition and the filter is made from at least one material selected from the group consisting of polyether sulfone, polyvinylidene fluoride, polycarbonate, and polytetrafluoroethylene.

Abstract: A liquid agent container includes the container's main unit, a cap, an intermediate member, and an internal stopper. The cap is provided with a liquid agent discharging path and an air introducing path. The intermediate member has a tube projecting toward the interior of the main unit. Between a liquid agent introducing path and the liquid agent discharging path a hydrophilic filter is provided, and between an air supplying path communicating with the air introducing path and an air delivering path a filter is provided. The air delivering path communicates with the interior of the main unit via a check valve, with an annular valve having an inner circumferential surface in contact with an outer circumferential surface of the tube, to pass air only in a direction toward the interior of the main unit. The present invention can provide a liquid agent container including a check valve readily fabricated and ensuring preventing a liquid agent from flowing back.

Abstract: An object of the present invention is to provide a novel strain that is capable of effectively inhibiting the growth of microorganisms such as fungi and Staphylococcus aureus, is safe, and does not influence the flavor and taste of foods. The present invention relates to a strain of Lactobacillus sanfranciscensis WB1006 (FERMABP-11246), and also relates to a food produced with the use of the strain.

Abstract: The object of the present invention is to provide an oral cavity composition which is nontoxic, excellent in plaque control, can prevent or treat onset of caries and periodontal disease caused by oral pathogens as well as can prevent or eliminate bad breath. The invention provides an oral cavity composition containing a lactic acid bacterium, Streptococcus faecalis as an active ingredient, the oral cavity composition wherein the lactic acid bacterium, Streptococcus faecalis is Streptococcus faecalis WB2000 strain and the oral cavity composition which is a non-aqueous oral cavity composition.

Abstract: A method for treating a patient having ulcerative colitis, by administering a drug which containing an effective amount of tetracyclines is provided. The drug may also contain penicillins and/or metronidazoles.

Abstract: The invention provides an aqueous ophthalmic composition, containing a beta blocker such as timolol, carteolol or the like, and a sugar alcohol such as mannitol, sorbitol or the like, optionally together with boric acid. The composition of the invention can improve the corneal permeability of a drug, so that the dose of the drug can be lowered, for example by decreasing the frequency of application to the eyes. It is therefore expected that the risk of systemic side effects which may be induced by the application of the beta blocker to the eyes, including cardiotoxicity or respiratory toxicity can be reduced. The decrease in the frequency of application of ophthalmic solution can favorably improve the QOL and prevent the decrease of therapeutic effect which may be caused by missing the application to the eyes.

Abstract: The invention provides an azithromycin-containing aqueous pharmaceutical composition, which comprises at least one member selected from the group consisting of azithromycin, and pharmaceutically acceptable salts thereof, and at least one member selected from the group consisting of monoethanolamine, diethanolamine, triethanolamine, and pharmaceutically acceptable salts thereof, and which does not comprise boric acid or pharmaceutically acceptable salts thereof, and a method for the preparation of the composition, wherein an azithromycin-containing liquid is maintained at pH of 4.0 or higher throughout the method for the preparation. The composition has good heat and storage stability.

Abstract: An object of the present invention is to provide a novel strain that is capable of effectively inhibiting the growth of microorganisms such as fungi and Staphylococcus aureus, is safe, and does not influence the flavor and taste of foods. The present invention relates to a strain of Lactobacillus sanfranciscensis WB1006 (FERM ABP-11246), and also relates to a food produced with the use of the strain.

Abstract: The present invention relates to a reversibly heat-gelable aqueous composition comprising a reversibly heat-gelable aqueous composition according to conventional technique, to which a thixotropic property-increasing substance is added. The thixotropic property-increasing substance is preferably at least one member selected from the group consisting of sugar alcohol, lactose, carmellose or pharmaceutically acceptable salts thereof and cyclodextrin. This composition can be stored at room temperature and accordingly, it is quite convenient for users to carry about the same.

Abstract: The invention provides a latanoprost-containing aqueous pharmaceutical composition filled in a filter-equipped container, with the adsorption of latanoprost by the filter being prevented. In the latanoprost-containing aqueous pharmaceutical composition filled in the filter-equipped container, a nonionic surfactant is contained in the composition and the filter is made from at least one material selected from the group consisting of polyether sulfone, polyvinylidene fluoride, polycarbonate, and polytetrafluoroethylene.

Abstract: Disclosed are pharmaceutical compositions of treatment for a patient with ulcerative colitis comprising a drug which can selectively kill Fusobacterium varium cells, or a drug which can neutralize the toxin produced by Fusobacterium varium cells, a method for screening such a drug, a method for treating a patient with the disease, a vaccine for the disease, a diagnostic drug, a diagnostic method, an experimental model for the disease and an experimental animal for the disease.

Abstract: The present invention has an object to provide an antibacterial aqueous pharmaceutical composition and an aqueous pharmaceutical composition which have a sufficiently low gelation temperature even when new quinolone antibacterial agents such as ofloxacin as the active ingredient and can be retained at the administration site for a long time by virtue of rapid viscosity increase after administration in spite of their being liquid at administration and thereby attain high availability of pharmaceutical agent. The present invention relates to an antibacterial aqueous pharmaceutical composition which comprises: 2.8 to 4 w/v % of methylcellulose, the 2 w/v % aqueous solution of which has a viscosity of 12 mPa·s or below at 20° C.; 1.5 to 2.3 w/v % of citric acid; 2 to 4 w/v % of polyethylene glycol; and 0.1 to 0.5 w/v % of ofloxacin.

Abstract: The object of the present invention is to provide an oral cavity composition which is nontoxic, excellent in plaque control, can prevent or treat onset of caries and periodontal disease caused by oral pathogens as well as can prevent or eliminate bad breath. The invention provides an oral cavity composition containing a lactic acid bacterium, Streptococcus faecalis as an active ingredient, the oral cavity composition wherein the lactic acid bacterium, Streptococcus faecalis is Streptococcus faecalis WB2000 strain and the oral cavity composition which is a non-aqueous oral cavity composition.

Abstract: The present invention has its object to provide a 2,3,4,5-tetrahydro-1H-1,5-benzodiazepine derivative represented with the Formula (1) or the pharmaceutically acceptable salt, which is effective as a therapeutic and prophylactic agent for diabetes, diabetic nephropathy, or glomerulosclerosis.

Abstract: A liquid drug container comprises a container body 1; a nozzle member 2 liquid-tightly mounted on the container body 1; and a nozzle cap 6 fitted on the nozzle member 2. A nozzle hole 231 of the nozzle member 2 is covered with a hydrophilic filer 3, and a top wall of the nozzle member 2 is provided with an air hole 24 covered with a hydrophobic filter 4. The nozzle member 2 may be provided with a filter-mounting member 8 for attachment of the filters. Also, the nozzle member 2 may be provided with a flow control member that controls air flowing into the container body through the air hole.

Abstract: The invention provides an azithromycin-containing aqueous pharmaceutical composition, which comprises at least one member selected from the group consisting of azithromycin, its anhydride, its hydrate, and pharmaceutically acceptable salts thereof, and at least one member selected from the group consisting of monoethanolamine, diethanolamine, triethanolamine, amino acid, ethylenediaminetetraacetic acid, and pharmaceutically acceptable salts thereof, and which does not comprise boric acid or pharmaceutically acceptable salts thereof, and a method for the preparation of the composition, wherein an azithromycin-containing liquid is maintained at pH of 4.0 or higher throughout the method for the preparation. The composition has good heat and storage stability.